^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

RAV 12

i
Other names: RAV12, anti-RAAG12 mAb, RAV 12
Associations
Trials
Company:
MacroGenics
Drug class:
Tumor-associated antigen inhibitor
Associations
Trials
over4years
[VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8)
|
RAV 12
over4years
[VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8)
|
RAV 12
over4years
[VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8)
|
RAV 12
almost5years
[VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8)
|
RAV 12